Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 1/20 | 0.52 |
| ▸ | ATP4B | P51164 | 1/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637598 | 1.00 | ATP4A (0.52) | ATP4AATP4BDDAH1POLBSLC40A1 | |
| SCHEMBL10726467 | 0.99 | ATP4A (0.51) | ATP4AATP4BDDAH1POLBSLC40A1 | |
| SCHEMBL9398029 | 0.87 | LMNA (0.48) | ATP4AATP4BDDAH1POLBLMNA | |
| SCHEMBL9396516 | 0.87 | ATP4A (0.40) | ATP4AATP4BLMNACYP1A2CYP2D6 | |
| SCHEMBL9396523 | 0.87 | ATP4A (0.40) | ATP4AATP4BPOLBLMNACYP1A2 | |
| SCHEMBL9398067 | 0.87 | ATP4A (0.42) | ATP4AATP4BDDAH1POLBLMNA | |
| SCHEMBL9677027 | 0.86 | KDM4E (0.39) | ATP4AATP4BPOLBLMNACYP1A2 | |
| SCHEMBL9675855 | 0.86 | ATP4A (0.41) | ATP4AATP4BPOLBLMNAALDH1A1 | |
| Leminoprazole SCHEMBL29895760 | 0.86 | ATP4A (0.39) | ATP4AATP4BDDAH1POLBLMNA | |
| SCHEMBL9395758 | 0.86 | ATP4A (0.39) | ATP4AATP4BBCHEALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1617842-A1 | ORAL PHARMACEUTICAL FORMULATIONS COMPRISING ACID-LABILE ACTIVE INGREDIENTS AND A WATER-SOLUBLE SUGAR DERIVATE, USE THEREOF AND THE SUITABLE PROCESS FOR MANUFACTURING THESE | Dr. Reddy's Laboratories Ltd. (IN) | 2006-01-25 | — | — | EP | claimed |
| US-20050031696-A1 | Oral pharmaceutical formulations of acid-labile active ingredients and process for making same | DR. REDDY'S LABORATORIES LIMITED | 2005-02-10 | — | — | US | claimed |
| WO-2004093875-A1 | ORAL PHARMACEUTICAL FORMULATIONS COMPRISING ACID-LABILE ACTIVE INGREDIENTS AND A WATER-SOLUBLE SUGAR DERIVATE, USE THEREOF AND THE SUITABLE PROCESS FOR MANUFACTURING THESE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2004-11-04 | — | — | WO | claimed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| EP-0565210-B1 | Vehicles for oral adminstration of pharmaceutically active acide labile substances | ASTRA AB (SE) | 1999-11-17 | — | — | EP | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| US-5869513-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1999-02-09 | — | — | US | claimed |
| EP-0502556-B1 | Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of acid labile compounds | HAESSLE AB (SE) | 1996-06-26 | — | — | EP | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| CN-1025151-C | Pharmaceutical formulations of acid labile substances for oral use | HAESSLE AB (SE) | 1994-06-29 | — | — | CN | claimed |
| EP-0244380-B1 | PHARMACEUTICAL FORMULATIONS OF ACID LABILE SUBSTANCES FOR ORAL USE | Aktiebolaget Hässle (SE) | 1993-01-07 | — | — | EP | claimed |
| EP-0502556-A1 | Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of acid labile compounds | Aktiebolaget Hässle (SE) | 1992-09-09 | — | — | EP | claimed |
| EP-0174717-B1 | BENZIMIDAZOLES, AND THEIR PRODUCTION FORMULATION AND USE AS GASTRIC ACID SECRETION INHIBITORS | FISONS plc (GB) | 1992-01-22 | — | — | EP | claimed |
| US-4853230-A | SUBCOATED; ENTERIC COATING; | AKTIEBOLAGET HASSLE (SE) | 1989-08-01 | — | — | US | claimed |
| CN-87103285-A | Pharmaceutical formulations of acid labile substances for oral administration | — | 1987-11-18 | — | — | CN | claimed |
| EP-0244380-A2 | Pharmaceutical formulations of acid labile substances for oral use | Aktiebolaget Hässle (SE) | 1987-11-04 | — | — | EP | claimed |
| EP-0232399-A1 | NEW AMINES, PROCESS FOR THEIR MANUFACTURE, THEIR USE AND MEDICINES CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1987-08-19 | — | — | EP | claimed |
| WO-1987001114-A2 | NEW AMINES, PROCESS FOR THEIR MANUFACTURE, THEIR USE AND MEDICINES CONTAINING THEM | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1987-02-26 | — | — | WO | claimed |
| EP-0204215-A1 | 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines | G.D. Searle & Co. (US) | 1986-12-10 | — | — | EP | claimed |
| EP-0174717-A1 | Benzimidazoles, and their production formulation and use as gastric acid secretion inhibitors | FISONS plc (GB) | 1986-03-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | ATP4A 1/4885ATP4B 8/4885DDAH1 21/4885 |
| US-20050031696-A1 | Oral pharmaceutical formulations of acid-labile active ingredients and process for making same | SI, GAA, PGA5 | ATP4A 2061/4885ATP4B 3332/4885DDAH1 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.